Alliqua (ALQA) Tops Q4 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Alliqua BioMedical, Inc. Reports Fourth Quarter and Fiscal Year 2015 Financial Results
February 23, 2016 7:00 AM ESTYARDLEY, Pa., Feb. 23, 2016 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (Nasdaq: ALQA) ("Alliqua" or "the Company"), a provider of advanced wound care products, today announced financial results for the fourth quarter and fiscal year ended December 31, 2015.
Fourth Quarter 2015 Summary:
Total revenue increased 187% year-over-year to $4.8 million. Organic revenue growth was approximately 38% year-over-year.Products revenue increased 216% year-over-year to $4.3 million. Organic product revenue growth was 32% year-over-year.Gross margin was 62%, compared to 47% in the same period last year and 67%. Product... MoreAlliqua BioMedical Announces Changes to Its Board of Directors
February 19, 2016 7:30 AM ESTLANGHORNE, Pa., Feb. 19, 2016 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (NASDAQ: ALQA) ("Alliqua" or "the Company"), today announced the appointment of Winston Kung to its Board of Directors. The Company also announced the departure of Perry Karsen from its Board of Directors.
Mr. Kung is the Vice President of Business Development and Global Alliances at Celgene Corporation. He worked previously as the Chief Business Officer at Celgene Cellular Therapeutics, a subsidiary of Celgene Corporation. Prior to joining Celgene Cellular Therapeutics, Mr. Kung was a Director in Citigroups Global Healthcare Corporate and... More
